{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:05:39Z","timestamp":1779509139386,"version":"3.53.1"},"reference-count":25,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2026,4,30]]},"DOI":"10.5582\/ddt.2026.01000","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T22:08:33Z","timestamp":1774908513000},"page":"190-198","source":"Crossref","is-referenced-by-count":0,"title":["Effects of Janus kinase inhibition and interleukin 6 inhibition on serum cytokine\/chemokine in idiopathic multicentric Castleman disease"],"prefix":"10.5582","volume":"20","author":[{"given":"Shoichi","family":"Fukui","sequence":"first","affiliation":[{"name":"Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."},{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Sumiyoshi","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."},{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Koga","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hosogaya","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawana","family":"Narita","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimpei","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Kamisawa","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieko","family":"Kiya","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Katsube","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Fajgenbaum DC, Uldrick TS, Bagg A, <i>et al<\/i>. International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease. Blood. 2017; 129:1646-1657.","DOI":"10.1182\/blood-2016-10-746933"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood. 2014; 123:2924-2933.","DOI":"10.1182\/blood-2013-12-545087"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Mukherjee S, Martin R, Sande B, Paige JS, Fajgenbaum DC. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy. Blood Adv. 2022; 6:359-367.","DOI":"10.1182\/bloodadvances.2021004441"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Fujimoto S, Koga T, Kawakami A, <i>et al.<\/i> Tentative diagnostic criteria and disease severity classification for Castleman disease: A report of the research group on Castleman disease in Japan. Mod Rheumatol. 2018; 28:161-167.","DOI":"10.1080\/14397595.2017.1366093"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T, Kishimoto S, Hirano T, Kishimoto T. Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman&apos;s disease. Blood. 1989; 74:1360-1367.","DOI":"10.1182\/blood.V74.4.1360.bloodjournal7441360"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Chan JY, Loh JW, Lim JQ, <i>et al.<\/i> Single-cell landscape of idiopathic multicentric Castleman disease in identical twins. Blood. 2024; 143:1837-1844.","DOI":"10.1182\/blood.2023021992"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Nishimoto N, Kanakura Y, Aozasa K, <i>et al.<\/i> Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005; 106:2627-2632.","DOI":"10.1182\/blood-2004-12-4602"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Van Rhee F, Wong RS, Munshi N, <i>et al.<\/i> Siltuximab for multicentric Castleman&apos;s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014; 15:966-974.","DOI":"10.1016\/S1470-2045(14)70319-5"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. van Rhee F, Voorhees P, Dispenzieri A, <i>et al<\/i>. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018; 132:2115-2124.","DOI":"10.1182\/blood-2018-07-862334"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Pierson SK, Stonestrom AJ, Shilling D, Ruth J, Nabel CS, Singh A, Ren Y, Stone K, Li H, van Rhee F, Fajgenbaum DC. Plasma proteomics identifies a &quot;chemokine storm&quot; in idiopathic multicentric Castleman disease. Am J Hematol. 2018; 93:902-912.","DOI":"10.1002\/ajh.25123"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. O&apos;Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: Impact on human disease and therapeutic intervention. Annu Rev Med. 2015; 66:311-328.","DOI":"10.1146\/annurev-med-051113-024537"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Pierson SK, Shenoy S, Oromendia AB, <i>et al<\/i>. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood Adv. 2021; 5:3445-3456.","DOI":"10.1182\/bloodadvances.2020004016"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Fukui S, Sumiyoshi R, Koga T, <i>et al.<\/i> A Phase Ib Investigator-Initiated Trial of Filgotinib in Patients With Idiopathic Multicentric Castleman Disease. Cureus. 2025; 17:e78865.","DOI":"10.7759\/cureus.78865"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Tanaka Y, Kavanaugh A, Wicklund J, McInnes IB. Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials. Mod Rheumatol. 2022; 32:1-11.","DOI":"10.1080\/14397595.2021.1902617"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, Gao J, Guo Y, Tasset C, Sundy JS, de Vlam K, Walker D, Takeuchi T. Effect of Filgotinib <i>vs<\/i> Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. JAMA. 2019; 322:315-325.","DOI":"10.1001\/jama.2019.9055"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Feagan BG, Danese S, Loftus EV Jr, <i>et al.<\/i> Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021; 397:2372-2384.","DOI":"10.1016\/S0140-6736(21)00666-8"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Fukui S, Sumiyoshi R, Koga T, Hosogaya N, Narita S, Morimoto S, Yano H, Katsube A, Yano S, Masaki Y, Tsunoda S, Sato S, Migita K, Kawakami A. Dynamics of Serum Cytokines and Chemokines in Patients With Idiopathic Multicentric Castleman Disease: From a Phase Ib Investigator-Initiated Trial of Filgotinib. Cureus. 2025; 17:e78974.","DOI":"10.7759\/cureus.78974"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Nishimura Y, Fajgenbaum DC, Pierson SK, <i>et al<\/i>. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. Am J Hematol. 2021; 96:1241-1252.","DOI":"10.1002\/ajh.26292"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Castell JV, Gomez-Lechon MJ, David M, Andus T, Geiger T, Trullenque R, Fabra R, Heinrich PC. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett. 1989; 242:237-239.","DOI":"10.1016\/0014-5793(89)80476-4"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990; 265:621-636.","DOI":"10.1042\/bj2650621"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113:1271-1276.","DOI":"10.1172\/JCI200420945"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005; 5:1731-1740.","DOI":"10.1016\/j.intimp.2005.05.010"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001; 97:14-32.","DOI":"10.1182\/blood.V97.1.14"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Heldin CH, Westermark B. Mechanism of action and <i>in vivo<\/i> role of platelet-derived growth factor. Physiol Rev. 1999; 79:1283-1316.","DOI":"10.1152\/physrev.1999.79.4.1283"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Iwaki N, Gion Y, Kondo E, Kawano M, Masunari T, Moro H, Nikkuni K, Takai K, Hagihara M, Hashimoto Y, Yokota K, Okamoto M, Nakao S, Yoshino T, Sato Y. Elevated serum interferon gamma-induced protein 10 kDa is associated with TAFRO syndrome. Sci Rep. 2017; 7:42316.","DOI":"10.1038\/srep42316"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/20\/2\/20_2026.01000\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T03:28:18Z","timestamp":1779506898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/20\/2\/20_2026.01000\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2026.01000","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"article-number":"2026.01000"}}